Abstract | BACKGROUND: STUDY OBJECTIVES: DESIGN: Randomized prospective study. PATIENTS: ASSESSMENTS: Patients were assessed before, during, and after treatment regarding symptoms, as well as results of laboratory values, chest radiograph examinations, and sputum bacterial cultures. RESULTS: We found few differences between the groups regarding cure rate, duration of IV medication, and occurrence of adverse effects with the tested therapies. However, clindamycin therapy was less expensive and was associated with a lower rate of posttreatment occurrence of methicillin-resistant Staphylococcus aureus. CONCLUSIONS:
|
Authors | Maiko Kadowaki, Yoshiki Demura, Shiro Mizuno, Daisuke Uesaka, Shingo Ameshima, Isamu Miyamori, Takeshi Ishizaki |
Journal | Chest
(Chest)
Vol. 127
Issue 4
Pg. 1276-82
(Apr 2005)
ISSN: 0012-3692 [Print] United States |
PMID | 15821205
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Thienamycins
- beta-Alanine
- panipenem-betamipron
- Clindamycin
- sultamicillin
- Ampicillin
- Sulbactam
|
Topics |
- Aged
- Aged, 80 and over
- Ampicillin
(administration & dosage)
- Anti-Bacterial Agents
(administration & dosage)
- Clindamycin
(administration & dosage)
- Female
- Humans
- Injections, Intravenous
- Male
- Pneumonia, Aspiration
(drug therapy)
- Prospective Studies
- Severity of Illness Index
- Sulbactam
(administration & dosage)
- Thienamycins
(administration & dosage)
- beta-Alanine
(administration & dosage, analogs & derivatives)
|